6A3 Monoclonal Antibody Nogo-A Binding Neuronal Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing neuronal regeneration in the adult central nervous system (CNS) are limited due to inhibitory molecules in the myelin environment, such as NogoA, which hinder axonal regeneration, and existing monoclonal antibodies have limitations in efficacy and stability.
Innovation Solution
A novel monoclonal human antibody, 6A3, with specific hypervariable regions, is developed to bind NogoA with high affinity, providing superior modulation of NogoA activity and extended half-life, allowing for slow release and local deposition at injury sites, enhancing neuronal regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing monoclonal antibodies are used to neutralize NogoA, then neurite growth inhibitory activity is reduced, but efficacy and stability are limited
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure to achieve superior properties. The 6A3 antibody was engineered with specific hypervariable regions that provide enhanced binding affinity to NogoA, improved stability, and extended half-life compared to existing antibodies like IN-1. This structural parameter optimization resolves the contradiction by maintaining neutralization efficacy while improving reliability.
Solution Approach 2:
The patent creates a copy or derivative of existing NogoA-neutralizing antibodies with improved characteristics. The 6A3 antibody serves as an optimized version that replicates the neutralization function of previous antibodies while incorporating modifications that enhance efficacy and stability, thereby resolving the limitation of existing antibodies.
2Reliability
If antibody dosing frequency is increased to maintain therapeutic levels, then neuronal regeneration efficacy improves, but treatment complexity and patient burden increase
Solution Approach 1:
The patent applies dynamics by extending the half-life of the antibody through structural modifications. The 6A3 antibody is designed to remain active in the cerebrospinal fluid for longer periods, allowing dynamic adjustment of dosing frequency from multiple times to less frequent administrations while maintaining therapeutic efficacy, thus reducing treatment complexity.
Solution Approach 2:
The patent enables periodic action by establishing an optimized dosing schedule based on the extended half-life of the 6A3 antibody. Instead of continuous or frequent dosing, the antibody can be administered at extended intervals while maintaining effective concentrations, thereby simplifying treatment protocols and reducing patient burden.
3Duration of action of moving object
If antibody half-life is extended for slow release, then dosing frequency is reduced, but localization precision at injury sites may be affected
Solution Approach 1:
The patent applies local quality by enabling the antibody to exhibit different behaviors in different locations. The 6A3 antibody is designed to circulate systemically with extended half-life while simultaneously achieving high localization precision at the injury site through specific binding to NogoA expressed at the lesion, thereby resolving the contradiction between prolonged duration and precise localization.
Solution Approach 2:
The patent uses NogoA itself as an intermediary that mediates between the extended half-life antibody and the injury site. The antibody circulates for extended periods in the cerebrospinal fluid and uses NogoA binding as a targeting mechanism to achieve precise localization at the injury site, thus reconciling prolonged duration with accurate positioning.
Data Source
AI summary
The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.